J&J COVID-19 shot gets better boost from Moderna or Pfizer in NIH study
14 Oct 2021
Johnson & Johnson (NYSE: JNJ) Inc is trading up 0.96% at 159.20
People who got Johnson & Johnson (NYSE: JNJ) Inc’s COVID-19 vaccine as a first shot had a stronger immune response when boosted with vaccines from Pfizer (NYSE: PFE) Inc/BioNTech SE or Moderna (NASDAQ: MRNA) Inc, a study run by the National Institutes of Health showed on Wednesday.
The study, which is preliminary and hasn’t been peer-reviewed, is the latest challenge to J&J’s efforts to use its COVID-19 vaccine as a booster in the United States.
The study, which included more than 450 adults who received initial shots from Pfizer, Moderna, or Johnson & Johnson, showed that “mixing and matching” booster shots of different types are safe in adults. Moderna’s and Pfizer’s vaccines are based on messenger RNA while J&J’s uses viral vector technology.
It comes as an advisory group to the U.S. Food and Drug Administration is preparing to meet later this week to discuss the merits of a booster shot for Moderna and J&J vaccines.
FDA officials on Wednesday said J&J’s regulatory submission for its planned booster raised red flags including small sample sizes and data based on tests that had not been validated.
U.S. health officials have been under pressure to offer advice on booster doses of the J&J and Moderna COVID-19 vaccines after the White House announced in August it planned to roll out boosters beginning last month for most adults.
The NIH study contrasted the safety and immune response of volunteers who were boosted with the same type of shot they had been given for their initial vaccination with those who received a different type of shot as a booster.
On technical fronts, Johnson & Johnson (NYSE: JNJ) Inc RSI stood at 34.56, and currently stock is trading below all MA. So, the SELL position can be taken with the following target and stop loss:
TRADE SIGNAL -: Johnson & Johnson (NYSE: JNJ) Inc – SELL: 159.20, TARGET: 157.68, STOP LOSS: 160.19